{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:50:18Z","timestamp":1792691418005,"version":"4.5.0"},"reference-count":169,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.lpm.2023.104168","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T04:01:50Z","timestamp":1690516910000},"page":"104168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Pulmonary arterial hypertension"],"prefix":"10.1016","volume":"52","author":[{"given":"Ath\u00e9na\u00efs","family":"Boucly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gerges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Savale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ja\u00efs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-6790","authenticated-orcid":false,"given":"Mitja","family":"Jevnikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-1951","authenticated-orcid":false,"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2023.104168_bib0001","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2023.104168_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020977300","article-title":"Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review","volume":"11","author":"Leber","year":"2021","journal-title":"Pulm Circ"},{"key":"10.1016\/j.lpm.2023.104168_bib0004","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1465-9921-11-73","article-title":"Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension","volume":"11","author":"Girerd","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.lpm.2023.104168_bib0006","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","article-title":"Epidemiology and treatment of pulmonary arterial hypertension","volume":"14","author":"Lau","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04229-2020","article-title":"Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation","volume":"58","author":"Montani","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0008","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1164\/rccm.201205-0886OC","article-title":"Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension","volume":"186","author":"Larkin","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102713","article-title":"The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: systematic review and meta-analysis","volume":"20","author":"Rubio-Rivas","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.lpm.2023.104168_bib0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.autrev.2012.07.010","article-title":"Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy","volume":"12","author":"Ruiz-Irastorza","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.lpm.2023.104168_bib0011","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.revmed.2011.01.002","article-title":"[Pulmonary arterial hypertension in systemic lupus erythematosus]","volume":"32","author":"Arnaud","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.lpm.2023.104168_bib0012","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1164\/ajrccm.155.3.9117037","article-title":"HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study","volume":"155","author":"Opravil","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0013","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1164\/rccm.200704-541OC","article-title":"Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era","volume":"177","author":"Sitbon","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0014","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1378\/chest.100.5.1268","article-title":"Primary pulmonary hypertension in HIV infection","volume":"100","author":"Speich","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0015","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0016-5085(91)90225-A","article-title":"Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics","volume":"100","author":"Hadengue","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2023.104168_bib0016","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/hep.21431","article-title":"Portopulmonary hypertension: results from a 10-year screening algorithm","volume":"44","author":"Krowka","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2023.104168_bib0017","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/jhep.2003.50060","article-title":"Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study","volume":"37","author":"Colle","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2023.104168_bib0018","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4065\/71.6.543","article-title":"Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients","volume":"71","author":"Castro","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.lpm.2023.104168_bib0019","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jhep.2020.02.021","article-title":"Portopulmonary hypertension in the current era of pulmonary hypertension management","volume":"73","author":"Savale","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2023.104168_bib0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hep.22275","article-title":"Clinical risk factors for portopulmonary hypertension","volume":"48","author":"Kawut","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2023.104168_bib0021","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/jlts.2002.31343","article-title":"Outcome of liver transplantation for patients with pulmonary hypertension","volume":"8","author":"Starkel","year":"2002","journal-title":"Liver Transpl"},{"issue":"25 Suppl","key":"10.1016\/j.lpm.2023.104168_bib0022","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0023","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0089-2019","article-title":"Schistosomiasis-associated pulmonary arterial hypertension: a systematic review","volume":"29","author":"Knafl","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.lpm.2023.104168_bib0024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrmicro801","article-title":"Schistosomiasis","volume":"2","author":"Chitsulo","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0025","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2023.104168_bib0026","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(13)61949-2","article-title":"Human schistosomiasis","volume":"383","author":"Colley","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2023.104168_bib0027","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1164\/rccm.201101-0146OC","article-title":"Praziquantel reverses pulmonary hypertension and vascular remodeling in murine schistosomiasis","volume":"184","author":"Crosby","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0028","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1378\/chest.11-0483","article-title":"The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension","volume":"141","author":"Fernandes","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0029","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jinf.2013.08.004","article-title":"Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension","volume":"68","author":"Mauad","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.lpm.2023.104168_bib0030","series-title":"Primary pulmonary hypertension: report on a WHO meeting, Geneva, 15-17 October 1973","author":"Hatano","year":"1975"},{"key":"10.1016\/j.lpm.2023.104168_bib0031","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00145608","article-title":"Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review","volume":"34","author":"Kovacs","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0032","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.00008611","article-title":"Pulmonary vascular resistances during exercise in normal subjects: a systematic review","volume":"39","author":"Kovacs","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0033","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jchf.2016.10.012","article-title":"The influence of age on hemodynamic parameters during rest and exercise in healthy individuals","volume":"5","author":"Wolsk","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.lpm.2023.104168_bib0034","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","article-title":"Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program","volume":"133","author":"Maron","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0035","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1164\/rccm.201706-1215OC","article-title":"Mild elevation of pulmonary arterial pressure as a predictor of mortality","volume":"197","author":"Douschan","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0036","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009729","article-title":"Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis","volume":"7","author":"Kolte","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.lpm.2023.104168_bib0037","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0038","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1152\/jappl.1949.2.1.24","article-title":"Pulmonary capillary pressure in man","volume":"2","author":"Hellems","year":"1949","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0039","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology","volume":"28","author":"Paulus","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2023.104168_bib0040","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1378\/chest.15-0928","article-title":"Hemodynamic thresholds for precapillary pulmonary hypertension","volume":"149","author":"Gerges","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0041","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2023.104168_bib0042","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/annrheumdis-2019-216476","article-title":"Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension","volume":"79","author":"Xanthouli","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2023.104168_bib0043","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30317-9","article-title":"Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study","volume":"8","author":"Maron","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0044","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","article-title":"Diagnosis and assessment of pulmonary arterial hypertension","volume":"54","author":"Badesch","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0045","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201211-2090CI","article-title":"Exercise-induced pulmonary hypertension: physiological basis and methodological concerns","volume":"187","author":"Naeije","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0046","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00578-2017","article-title":"An official European Respiratory Society statement: pulmonary haemodynamics during exercise","volume":"50","author":"Kovacs","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0047","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1161\/CIRCULATIONAHA.112.000667","article-title":"Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases","volume":"128","author":"Lewis","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0048","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1183\/09031936.00021915","article-title":"Criteria for diagnosis of exercise pulmonary hypertension","volume":"46","author":"Herve","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0049","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2020.08.2110","article-title":"Exercise pulmonary resistances predict long-term survival in systemic sclerosis","volume":"159","author":"Zeder","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0050","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCHEARTFAILURE.110.959437","article-title":"Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes","volume":"4","author":"Lewis","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.lpm.2023.104168_bib0051","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.chest.2016.02.634","article-title":"Pressure-flow during exercise catheterization predicts survival in pulmonary hypertension","volume":"150","author":"Hasler","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0052","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1183\/13993003.00990-2016","article-title":"Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis","volume":"48","author":"Stamm","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0053","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2019.10.048","article-title":"Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0054","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0055","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension. A national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0056","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1160\/TH12-04-0239","article-title":"Non-invasive algorithms for the diagnosis of pulmonary hypertension","volume":"108","author":"Bonderman","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2023.104168_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168706","article-title":"Use of ECG and other simple non-invasive tools to assess pulmonary hypertension","volume":"11","author":"Kovacs","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.lpm.2023.104168_bib0058","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.118.039360","article-title":"Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension","volume":"139","author":"Chin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0059","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1378\/chest.06-1758","article-title":"N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension","volume":"131","author":"Leuchte","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0060","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1183\/09031936.00160307","article-title":"Biomarkers in pulmonary hypertension","volume":"32","author":"Warwick","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0061","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","volume":"18","author":"Galderisi","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.lpm.2023.104168_bib0062","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.lpm.2023.104168_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.lpm.2023.104168_bib0064","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","volume":"23","author":"Rudski","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.lpm.2023.104168_bib0065","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thorax.57.6.473","article-title":"Peripheral airway obstruction in primary pulmonary hypertension","volume":"57","author":"Meyer","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.lpm.2023.104168_bib0066","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0735-1097(02)02964-9","article-title":"Pulmonary function in primary pulmonary hypertension","volume":"41","author":"Sun","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0067","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1161\/CIRCULATIONAHA.112.126755","article-title":"Abnormal lung function in adults with congenital heart disease: prevalence, relation to cardiac anatomy, and association with survival","volume":"127","author":"Alonso-Gonzalez","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0068","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S2213-2600(22)00097-2","article-title":"Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis","volume":"10","author":"Hoeper","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0069","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/hc2901.093198","article-title":"Exercise pathophysiology in patients with primary pulmonary hypertension","volume":"104","author":"Sun","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0070","first-page":"774","article-title":"Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis","volume":"103","author":"Dumitrescu","year":"2017","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.lpm.2023.104168_bib0071","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0072","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.116.022362","article-title":"Systemic consequences of pulmonary hypertension and right-sided heart failure","volume":"141","author":"Rosenkranz","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0073","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"53","author":"Morrell","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0074","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ng.2844","article-title":"EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension","volume":"46","author":"Eyries","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.lpm.2023.104168_bib0075","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","article-title":"Identification of rare sequence variation underlying heritable pulmonary arterial hypertension","volume":"9","author":"Gr\u00e4f","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.lpm.2023.104168_bib0076","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0077","doi-asserted-by":"crossref","first-page":"K9","DOI":"10.1093\/eurheartj\/suz204","article-title":"Screening strategies for pulmonary arterial hypertension","volume":"21","author":"Kiely","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.lpm.2023.104168_bib0078","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0079","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1378\/chest.11-0676","article-title":"The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension","volume":"141","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0081","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Gali\u00e8","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0082","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2023.104168_bib0083","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"Galie","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0084","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2023.104168_bib0085","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02419-2021","article-title":"External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry","volume":"59","author":"Boucly","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0086","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02311-2021","article-title":"COMPERA 2.0: a refined 4-strata risk assessment model for pulmonary arterial hypertension","volume":"60","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0087","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0088","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2023.104168_bib0089","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijcard.2018.05.127","article-title":"Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension","volume":"270","author":"Groth","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0090","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/thx.51.2.202","article-title":"Assessment of oxygen supplementation during air travel","volume":"51","author":"Cramer","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.lpm.2023.104168_bib0091","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1378\/chest.11-2016","article-title":"Effects of commercial air travel on patients with pulmonary hypertension air travel and pulmonary hypertension","volume":"142","author":"Roubinian","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0092","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.chest.2020.09.004","article-title":"Effect of normobaric hypoxia on exercise performance in pulmonary hypertension: randomized trial","volume":"159","author":"Schneider","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0093","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000532","article-title":"Right heart function during simulated altitude in patients with pulmonary arterial hypertension","volume":"4","author":"Seccombe","year":"2017","journal-title":"Open Heart"},{"key":"10.1016\/j.lpm.2023.104168_bib0094","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/2045-8932.83451","article-title":"Air travel can be safe and well tolerated in patients with clinically stable pulmonary hypertension","volume":"1","author":"Thamm","year":"2011","journal-title":"Pulm Circ"},{"key":"10.1016\/j.lpm.2023.104168_bib0095","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1378\/chest.12-0993","article-title":"Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension","volume":"143","author":"Chan","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0096","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1183\/09031936.00027909","article-title":"Effects of exercise training in patients with idiopathic pulmonary arterial hypertension","volume":"34","author":"de Man","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0097","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/eurheartj\/ehv337","article-title":"Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial","volume":"37","author":"Ehlken","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2023.104168_bib0098","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00332-2018","article-title":"ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension","volume":"53","author":"Gr\u00fcnig","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0099","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/eurheartj\/ehaa696","article-title":"Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial","volume":"42","author":"Gr\u00fcnig","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2023.104168_bib0100","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.106.618397","article-title":"Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension","volume":"114","author":"Mereles","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.667602","article-title":"Prevalence of mental disorders and impact on quality of life in patients with pulmonary arterial hypertension","volume":"12","author":"Olsson","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.lpm.2023.104168_bib0102","doi-asserted-by":"crossref","first-page":"K46","DOI":"10.1093\/eurheartj\/suz207","article-title":"The practical management of fluid retention in adults with right heart failure due to pulmonary arterial hypertension","volume":"21","author":"Stickel","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.lpm.2023.104168_bib0103","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","article-title":"Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)","volume":"129","author":"Olsson","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0106","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.115.018435","article-title":"Effect of Warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL)","volume":"132","author":"Preston","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0107","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/jcsm.12764","article-title":"Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study","volume":"12","author":"Kramer","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.lpm.2023.104168_bib0108","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00616-2020","article-title":"Oral iron supplementation with ferric maltol in patients with pulmonary hypertension","volume":"56","author":"Olsson","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0109","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijcard.2014.04.233","article-title":"Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study","volume":"175","author":"Viethen","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-38664-0_9","article-title":"Endothelin receptor antagonists","volume":"218","author":"Clozel","year":"2013","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.lpm.2023.104168_bib0111","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1038\/s41598-017-09178-1","article-title":"In vitro micropatterned human pluripotent stem cell test (microP-hPST) for morphometric-based teratogen screening","volume":"7","author":"Xing","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.lpm.2023.104168_bib0112","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0113","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0114","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","article-title":"Results of European post-marketing surveillance of bosentan in pulmonary hypertension","volume":"30","author":"Humbert","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5414\/CPP44113","article-title":"Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol","volume":"44","author":"van Giersbergen","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.lpm.2023.104168_bib0116","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","article-title":"Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension","volume":"60","author":"Paul","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.lpm.2023.104168_bib0117","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/00912709922008380","article-title":"Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin","volume":"39","author":"Weber","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.lpm.2023.104168_bib0118","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","article-title":"Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects","volume":"48","author":"Wrishko","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.lpm.2023.104168_bib0119","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lpm.2023.104168_bib0121","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Galie","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0122","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0123","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study","volume":"43","author":"Sastry","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0124","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0125","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0126","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0127","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF03256644","article-title":"Prostanoids for pulmonary arterial hypertension","volume":"2","author":"Galie","year":"2003","journal-title":"Am J Respir Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0128","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0026-895X(25)10547-6","article-title":"Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades","volume":"48","author":"Jones","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.lpm.2023.104168_bib0129","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ahj.2013.08.007","article-title":"EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension","volume":"167","author":"Sitbon","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.lpm.2023.104168_bib0130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0131","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0132","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0133","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0134","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chest.2015.11.005","article-title":"Treprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system: results of the delivery for PAH trial","volume":"150","author":"Bourge","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0135","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.healun.2018.06.006","article-title":"Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension","volume":"37","author":"Richter","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.lpm.2023.104168_bib0136","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0137","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0138","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0139","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104168_bib0140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0141","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0142","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Galie","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0143","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2023.104168_bib0144","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0145","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0146","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/eurheartj\/ehq170","article-title":"Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension","volume":"31","author":"Montani","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2023.104168_bib0147","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.healun.2020.09.011","article-title":"Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry","volume":"39","author":"Hoeper","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.lpm.2023.104168_bib0148","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension","volume":"204","author":"Boucly","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0149","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1183\/09031936.00116313","article-title":"Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study","volume":"43","author":"Sitbon","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0150","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01906-2018","article-title":"Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension","volume":"53","author":"Hoeper","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0151","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03087-2021","article-title":"Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation","volume":"60","author":"Olsson","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0152","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/303059","article-title":"Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor\u2013II gene","volume":"67","author":"Deng","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.lpm.2023.104168_bib0153","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/01.CIR.0000012754.72951.3D","article-title":"Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor","volume":"105","author":"Atkinson","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0154","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/hc3201.094152","article-title":"Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-\u03b2 1 and bone morphogenetic proteins","volume":"104","author":"Morrell","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0155","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02341-2020","article-title":"Targeting transforming growth factor-\u03b2 receptors in pulmonary hypertension","volume":"57","author":"Guignabert","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0156","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0157","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.98.11030554","article-title":"Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients","volume":"11","author":"Humbert","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0158","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.201006-0905OC","article-title":"C-Kit\u2013positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension","volume":"184","author":"Montani","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0159","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/rccm.200707-1037OC","article-title":"Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension","volume":"178","author":"Perros","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0160","doi-asserted-by":"crossref","first-page":"eaaz5660","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0161","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0162","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104168_bib0163","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lpm.2023.104168_bib0164","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0165","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.113.001460","article-title":"Impression, sunset","volume":"127","author":"Humbert","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2023.104168_bib0166","doi-asserted-by":"crossref","first-page":"00433","DOI":"10.1183\/23120541.00433-2022","article-title":"AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study","volume":"9","author":"Gillies","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.lpm.2023.104168_bib0167","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02356-2021","article-title":"Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension","author":"Galkin","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104168_bib0168","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211057071","article-title":"TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension","volume":"11","author":"Frantz","year":"2021","journal-title":"Pulm Circ"},{"key":"10.1016\/j.lpm.2023.104168_bib0169","series-title":"Seralutinib for the treatment of pulmonary arterial hypertension (PAH): results from the phase 2 torrey trial","first-page":"A6726","author":"Frantz","year":"2023"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498223000052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498223000052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:21Z","timestamp":1760105361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498223000052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":169,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0755498223000052"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2023.104168","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2023.104168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104168"}}